130 related articles for article (PubMed ID: 37639758)
1. Development of 5-fluorouracil-dichloroacetate mutual prodrugs as anticancer agents.
Mironiuk-Puchalska E; Karatsai O; Żuchowska A; Wróblewski W; Borys F; Lehka L; Rędowicz MJ; Koszytkowska-Stawińska M
Bioorg Chem; 2023 Nov; 140():106784. PubMed ID: 37639758
[TBL] [Abstract][Full Text] [Related]
2. Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
Ciaffaglione V; Modica MN; Pittalà V; Romeo G; Salerno L; Intagliata S
ChemMedChem; 2021 Dec; 16(23):3496-3512. PubMed ID: 34415107
[TBL] [Abstract][Full Text] [Related]
3. Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary
Salerno L; Vanella L; Sorrenti V; Consoli V; Ciaffaglione V; Fallica AN; Canale V; Zajdel P; Pignatello R; Intagliata S
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1378-1386. PubMed ID: 34167427
[TBL] [Abstract][Full Text] [Related]
4. Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
Jiang Y; Li X; Hou J; Huang Y; Jia Y; Zou M; Zhang J; Wang X; Xu W; Zhang Y
Eur J Med Chem; 2016 Oct; 121():649-657. PubMed ID: 27322756
[TBL] [Abstract][Full Text] [Related]
5. Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells.
Salerno L; Sorrenti V; Pittalà V; Consoli V; Modica MN; Romeo G; Marrazzo A; Giuliano M; Zajdel P; Vanella L; Intagliata S
ChemMedChem; 2023 Apr; 18(8):e202300047. PubMed ID: 36756924
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity of the seaweed compound fucosterol, alone and in combination with 5-fluorouracil, in colon cells using 2D and 3D culturing.
Ramos AA; Almeida T; Lima B; Rocha E
J Toxicol Environ Health A; 2019; 82(9):537-549. PubMed ID: 31258008
[TBL] [Abstract][Full Text] [Related]
7. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs.
Daumar P; Decombat C; Chezal JM; Debiton E; Madesclaire M; Coudert P; Galmier MJ
Eur J Med Chem; 2011 Jul; 46(7):2867-79. PubMed ID: 21530016
[TBL] [Abstract][Full Text] [Related]
9. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
10. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
11. Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro.
Shiiki S; Fuchimoto S; Iwagaki H; Akazai Y; Matsubara N; Watanabe T; Orita K
Acta Med Okayama; 1991 Oct; 45(5):339-45. PubMed ID: 1836706
[TBL] [Abstract][Full Text] [Related]
12. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
13. The prodrugs of 5-fluorouracil.
Malet-Martino M; Jolimaitre P; Martino R
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):267-310. PubMed ID: 12678747
[TBL] [Abstract][Full Text] [Related]
14. Studies of anticancer drug cytotoxicity based on long-term HepG2 spheroid culture in a microfluidic system.
Zuchowska A; Kwapiszewska K; Chudy M; Dybko A; Brzozka Z
Electrophoresis; 2017 Apr; 38(8):1206-1216. PubMed ID: 28090668
[TBL] [Abstract][Full Text] [Related]
15. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Takahashi K; Tanaka M; Inagaki A; Wanibuchi H; Izumi Y; Miura K; Nagayama K; Shiota M; Iwao H
Int J Oncol; 2013 Dec; 43(6):1985-91. PubMed ID: 24126575
[TBL] [Abstract][Full Text] [Related]
17. A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier.
Li M; Liang Z; Sun X; Gong T; Zhang Z
PLoS One; 2014; 9(11):e112888. PubMed ID: 25389968
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of a Conjugate of 5-Fluorouracil and an LSD1 Inhibitor.
Ota Y; Nakamura A; Elboray EE; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):192-195. PubMed ID: 30369513
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Vodenkova S; Buchler T; Cervena K; Veskrnova V; Vodicka P; Vymetalkova V
Pharmacol Ther; 2020 Feb; 206():107447. PubMed ID: 31756363
[TBL] [Abstract][Full Text] [Related]
20. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
